Translate Page To German Tranlate Page To Spanish Translate Page To French Translate Page To Italian Translate Page To Japanese Translate Page To Korean Translate Page To Portuguese Translate Page To Chinese
  Number Times Read : 1    Word Count: 677  
Categories

Arts & Entertainment
Business
Career
Cars and Trucks
Celebrities
Communications
Computers
Culture and Society
Disease & Illness
Environment
Fashion
Finance
Food & Beverage
Health & Fitness
Hobbies
Home & Family
Inspirational
Internet Business
Legal
Online Shopping
Pets & Animals
Politics
Product Reviews
Recreation & Sports
Reference & Education
Religion
Self Improvement
Travel & Leisure
Vehicles
Womens Issues
Writing & Speaking
 


   

Cell Free DNA (cfDNA) Testing Market Projected to Garner Significant Revenues by 2024



[Valid RSS feed]  Category Rss Feed - http://articlespromoter.com/rss.php?rss=280
By : Sneha Talanakr    zero times read
Submitted 2019-07-11 13:39:17
Cell-Free DNA are fragments of DNA which circulate in the blood fluid and can be utilized as valuable biomarkers. It is a new technology in which small quantity of liquid sample (saliva, urine, or blood) from the patient is collected to examine the freely flowing DNA. Cell-Free DNA (cfDNA) is a noninvasive screening test used to help detect graft rejection, identify mutations in cancer patients and detect various chromosomal abnormalities in the fetus, in order to know the gender of fetus. The discovery of cfDNA has opened up to new potentials in the field of oncology, gynecology, transplantation and infectious diseases.

Read Report Overview: https://www.transparencymarketresearch.com/cellfree-dna-testing-market.html

The cell-free DNA testing market is segmented on basis of its application, types and region. On basis of application the market is segmented into oncology, gynecology and transplantation. By type, the market is further segmented into donor derived cell free DNA (ddcfDNA), circulating cell-free tumor DNA (ctDNA) and cell-free fetal DNA (NIPT). Donor-derived cell-free DNA testing examines the graft rejection in transplanted patient by recognizing the absence or presence of donor DNA in the bloodstream. In ctDNA testing, circulating tumor DNA in urine, saliva or blood of tumor patients is examined to detect mutation. In prenatal testing, the chromosomal abnormality is identified in the fetus by collection of blood sample from pregnant women who carry DNA of that fetus.

The cell-free fetal DNA market has a major share in the market due to increased number of pregnancies following to it is the circulating cell-free tumor DNA market and later the donor derived cell-free DNA market. In the region wise segmentation, North America region had the largest revenue in 2015 due to majority of tests launched and adaptation of advanced technologies in screening techniques. Following North America is Europe and Asia Pacific which are also the fastest growing market due to blooming economy and improving healthcare infrastructure and rising prevalence of diseases in these regions. The potential of cell-free DNA testing market has attracted many biotechnology and pharmaceutical firms by acquiring other major firms or by launching novel tests.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8203

Increased incidences of diseases like chromosomal abnormalities due to increase in maternal age, changing lifestyle, unhealthy diet habits and rising prevalence of cancer, also in addition to it increasing healthcare expenditure and rising healthcare awareness are the reasons driving the cell-free DNA market. However, there are some other factors such as lack of skilled healthcare professionals, high test cost, non-affordability in low income countries, ethical issues related to genetic testing, lack of standardization, unfavorable reimbursement policies and legal and regulatory guidelines some of the reasons hampering the growth of the market.

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14162

Various companies are coming up with new software’s and improved sequencing technologies which has improved the test quality with accurate and rapid results. Some of the leading players in cell-free DNA testing market are Agilent Technology, Allenex AB, Biocept, Inc., Biodesix, Inc., CareDx, Inc. Guardant Health, Inc., Illumania, Inc., Inivated Limited, Natera, Inc., Quest Diagnostics, Roche Holdings AG, Sequenom, Inc. and Trovagene, Inc. The global cell-free DNA testing market is a competitive market and all the players are involved in developing new assays by mergers and acquisitions In order to sustain themselves in the market and maintain their market share. For instance, Roche Holdings AG received U.S. FDA approval for its newly launched ctDNA test Cobas which is approved for blood based genetic tests. Roche also entered the NIPT market with acquisition of Ariosa diagnostics. CareDx, Inc., acquired Allenex AB for its new developments in donor derived Cell-Free DNA tests for kidney and heart transplant patients.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.
Author Resource:- Transparency Market Research
Article From Articles Promoter Article Directory

HTML Ready Article. Click on the "Copy" button to copy into your clipboard.




Firefox users please select/copy/paste as usual
New Members
select
Sign up
select
learn more
Affiliate Sign in
Affiliate Sign In
 
Nav Menu
Home
Login
Submit Articles
Submission Guidelines
Top Articles
Link Directory
About Us
Contact Us
Privacy Policy
RSS Feeds

Actions
Print This Article
Add To Favorites

 

Free Article Submission

Website Security Test